Ascending Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of BLI-489 Administered Intravenously to Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2009
At a glance
- Drugs BLI 489 (Primary)
- Indications Bacterial infections
- Focus Adverse reactions
- 18 Jul 2009 Actual patient number (54) added as reported by ClinicalTrials.gov.
- 18 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 May 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.